DEEPLY COMMITTED TO PATIENTS

Welcome to TG Therapeutics, where our mission is clear and unwavering: to boldly advance innovative medicines for people living with B-cell–driven diseases.

From the very beginning, our focus has been on delivering meaningful progress for those who urgently need treatment options. That commitment came to life with BRIUMVI, an FDA-approved treatment for relapsing forms of multiple sclerosis.  BRIUMVI is both a milestone and a foundation—informing how we think, how we innovate, and how we advance the next generation of B-cell–focused therapies.

Guided by our deep understanding of B-cell biology, we are building a pipeline driven by innovation, precision, and purpose. For many of us at TG Therapeutics, this mission is personal. Our connection to B-cell diseases comes through loved ones, friends, colleagues, and members of our own TG team living with multiple sclerosis. These experiences strengthen our commitment and determination, and the passion, grit, and dedication of our team continues to inspire me every day. Together, we think big, take bold action, and remain fearless in our pursuit of better outcomes.

We will continue to challenge ourselves, advance our science, and move with urgency—because we know there are people counting on us.

Sincerely,

Michael S. Weiss
CEO – TG Therapeutics